…
Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is headquartered in Red Bank, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Canton Strategic Holdings, Inc. (NASDAQ: CNTN) are limited; the company provides little detail about operations or revenue sources. Long-term growth drivers are not clearly articulated and would likely depend on execution of any stated investment strategy and underlying asset performance, which investors should monitor. Some investors may find exposure to its strategic initiatives attractive despite information gaps.
Material risks include limited transparency and disclosure, thin trading liquidity, governance and execution risk, and possible information gaps that could affect investor assessment.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -42.10M | -12.20M | -9.32M | -8.47M | -2.21M |
| Net income | -35.92M | -12.20M | -9.32M | -8.47M | -2.21M |
| Selling general administrative | 17.03M | 6.04M | 5.90M | 4.60M | 1.37M |
| Ebit | - | -12.21M | -9.30M | -6.88M | - |
| Ebitda | -20.11M | -12.43M | -9.15M | -6.65M | -1.38M |
| Depreciation and amortization | - | -0.22M | 0.15M | 0.23M | - |
| Operating income | -20.11M | -12.43M | -9.46M | -6.88M | -3.21M |
| Other operating expenses | 20.11M | 12.43M | 9.46M | 6.88M | 3.21M |
| Interest expense | 0.03M | 0.01M | 0.02M | 1.59M | 0.83M |
| Tax provision | -6.19M | 0.00M | - | - | - |
| Interest income | 0.04M | 0.25M | 0.15M | 0.00M | - |
| Net interest income | 0.01M | 0.24M | 0.14M | -1.59M | -0.83M |
| Income tax expense | -6.19M | - | - | - | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 20.11M | 12.43M | 9.46M | 6.88M | 3.21M |
| Total other income expense net | -22.00M | 0.24M | 0.14M | -1.59M | 1.00M |
| Net income from continuing ops | -35.92M | -12.20M | -9.32M | -8.47M | -2.21M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 519.15M | 3.72M | 10.95M | 6.69M | 0.62M |
| Intangible assets | 501.76M | - | - | - | - |
| Other current assets | 0.35M | 0.16M | 0.01M | 0.18M | 0.62M |
| Total liab | 121.22M | 2.41M | 1.82M | 1.14M | 5.31M |
| Total stockholder equity | 397.93M | 1.31M | 9.13M | 5.54M | -4.68M |
| Other current liab | 2.20M | 1.32M | 0.91M | 0.19M | 1.68M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -72.82M | -36.90M | -24.70M | -15.38M | -6.91M |
| Cash | 17.03M | 3.56M | 10.94M | 6.51M | 0.00M |
| Total current liabilities | 3.29M | 2.41M | 1.82M | 1.14M | 4.53M |
| Net debt | -17.03M | -3.56M | -10.94M | -6.51M | 2.16M |
| Short term debt | - | - | - | - | 1.39M |
| Short long term debt | - | - | - | - | 1.39M |
| Short long term debt total | - | - | - | - | 2.17M |
| Other stockholder equity | 470.74M | 38.21M | 33.83M | 20.93M | 2.23M |
| Total current assets | 17.39M | 3.72M | 10.95M | 6.69M | 0.62M |
| Long term debt | - | - | - | - | 0.77M |
| Accounts payable | 1.09M | 1.09M | 0.91M | 0.95M | 1.46M |
| Non currrent assets other | 501.76M | 0.12M | - | - | 0.55M |
| Non current assets total | 501.76M | 0.12M | 0.00M | 0.00M | 0.55M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total cashflows from investing activities | -77.57M | - | - | - | - |
| Net borrowings | -0.22M | 0.00M | 0.00M | -0.01M | 1.08M |
| Total cash from financing activities | 107.17M | 3.53M | 11.72M | 13.06M | 0.90M |
| Net income | -35.92M | -12.20M | -9.32M | -8.47M | -2.21M |
| Change in cash | 13.47M | -7.38M | 4.42M | 6.51M | -0.19M |
| Begin period cash flow | 3.56M | 10.94M | 6.51M | 0.00M | 0.19M |
| End period cash flow | 17.03M | 3.56M | 10.94M | 6.51M | 0.00M |
| Total cash from operating activities | -16.13M | -10.90M | -7.30M | -6.56M | -1.09M |
| Issuance of capital stock | 115.67M | 4.19M | 12.23M | 13.65M | 0.00M |
| Depreciation | 0.02M | - | - | - | - |
| Other cashflows from investing activities | -77.57M | - | - | - | - |
| Sale purchase of stock | - | - | 0.00M | -0.07M | 0.00M |
| Other cashflows from financing activities | 107.17M | -0.66M | -0.51M | -0.50M | -0.18M |
| Capital expenditures | 77.57M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.99M | 0.56M | 0.84M | -0.57M | 1.05M |
| Stock based compensation | 2.88M | 0.71M | 0.83M | 0.80M | 1.24M |
| Other non cash items | 23.07M | 0.02M | 0.35M | 1.68M | -1.17M |
| Free cash flow | -16.13M | -10.90M | -7.30M | -6.56M | -1.09M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CNTN Canton Strategic Holdings, Inc. |
-0.12 7.62% |
1.51 | - | - | 108.93 | 0.37 | 107.15 | -6.32 |
| NVO Novo Nordisk A/S |
-1.21 2.90% |
40.40 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.15 1.14% |
531.64 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.70 0.49% |
957.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is headquartered in Red Bank, New Jersey.
34 Shrewsbury Avenue, Red Bank, NJ, United States, 07701
732 889 3111
12
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark Wendland | CEO & Chairman of the Board | 1979 |
| Mr. Mark Toomey | President | 1971 |
| Mr. Jacob Asbury | Chief Financial Officer | 1974 |
| Ms. Angela Dominy Radkowski | Chief Operating Officer | 1989 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.